Home / Therapeutic Area / Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017

Published: May 2017 | Published By: GBI Research

Description

This report provides an overview of the genetic disorders pipeline landscape, specifically focusing on muscular dystrophies. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Becker and Duchenne Muscular Dystrophy (BMD and DMD) and features dormant and discontinued projects. Both indications covered are inherited muscular dystrophies, a group of genetic, degenerative diseases primarily affecting voluntary muscles.

BMD, the first type of muscular dystrophy, leads to symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls. DMD is a condition which causes muscle weakness, and is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

The size of these two pipelines ranges from just six in BMD to 108 in DMD. The majority of pipeline products for DMD target dystrophin which, as mentioned, is the causative gene for the disease. However, a number of products act on other molecular targets such as growth differentiation factor 8, nuclear factor kappa B and utrophin. The first two of these make up the pipeline for BMD, along with forkhead box protein 1B.

Scope

  • Which companies are the most active within the pipeline for genetic disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of genetic disorder therapeutics?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Executive Summary
Table of Contents
List of Tables
List of Figures
Introduction
Genetic Disorder Cluster Muscular Dystrophy Report Coverage
Becker Muscular Dystrophy – Overview
Duchenne Muscular Dystrophy – Overview
Therapeutics Development
Becker Muscular Dystrophy
Duchenne Muscular Dystrophy
Therapeutics Assessment
Becker Muscular Dystrophy
Duchenne Muscular Dystrophy
Companies Involved in Therapeutics Development
Becker Muscular Dystrophy
Duchenne Muscular Dystrophy
Dormant Projects
Becker Muscular Dystrophy
Duchenne Muscular Dystrophy
Discontinued Products
Duchenne Muscular Dystrophy
Product Development Milestones
Duchenne Muscular Dystrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +